via National Cancer Institute
Scientists are reporting development and successful lab tests on the first potential drug to pack a lethal one-two punch against melanoma skin cancer cells.
Hit number one destroys cells in the main tumor, and the second hit blocks the spread of the cancer to other sites in the body, according to their report in the journal ACS Chemical Biology.
Nathan Luedtke and colleagues explain that the spread of melanoma and other forms of cancer beyond the original location — a process called metastasis — makes cancer such a serious disease. Photodynamic therapy (PDT), which involves administering a drug that kills cancer cells when exposed to light, already is available. But PDT works only on the main tumor and has other drawbacks. Luedtke’s team set out to find an improved approach to PDT.
The scientists describe successful tests in laboratory mice of one compound they synthesized that not only killed melanoma cells, but also stopped them from metastasizing by blocking a key signal inside the tumor cells. The compound “provides the first example of a preclinical candidate possessing both of these properties,” the scientists state.
The Latest Bing News on:
Melanoma
- LINC00470 accelerates the proliferation and metastasis of melanoma through promoting APEX1 expressionon April 19, 2021 at 2:53 pm
Recently studies found that APEX1 was abnormally expressed in melanoma, indicating that it might be involved in the development of melanoma. However, the underlying mechanism and the interaction ...
- Flavonoids increase melanin production and reduce proliferation, migration and invasion of melanoma cells by blocking endolysosomal/melanosomal TPC2on April 19, 2021 at 12:09 pm
Two-pore channel 2 (TPC2) resides in endolysosomal membranes but also in lysosome-related organelles such as the melanin producing melanosomes. Gain-of-function polymorphisms in hTPC2 are associated ...
- Darovasertib Shows Encouraging Activity in Metastatic Uveal Melanomaon April 19, 2021 at 10:42 am
Darovasertib, both as a single agent and in combination with binimetinib, has demonstrated promising early activity in patients with metastatic uveal melanoma, according to preliminary data from an ...
- Viewpoint Molecular Targeting(TM) Presents Positive Preclinical Results of VMT01 at the 10th World Congress of Melanomaon April 19, 2021 at 8:13 am
Company is launching Phase 1 imaging study of VMT01 imminently with provisional results expected in Q4 2021, followed by Phase 1/2a therapy study for the treatment of metastatic melanoma - CORALVILLE, ...
- Video Dermatoscope Market to Gain Traction; Increasing Prevalence of Melanoma Worldwide to Stoke Demand: Fortune Business Insights™on April 19, 2021 at 5:36 am
The global video dermotoscope market size is expected to showcase a considerable growth owing to the increasing ...
- OptumInsight Study Describes Cost Savings of DermTech’s Pigmented Lesion Assay in the Management of Melanomaon April 15, 2021 at 1:01 pm
DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the topline results from its second economic study of the Pigmented Lesion Assay, a ...
- Made-to-Order TILs Effective Against Metastatic Melanomaon April 14, 2021 at 5:00 pm
Cell therapy with tumor-infiltrating lymphocytes (TILs) extracted from tumor tissue yielded responses in patients with heavily pretreated malignant melanoma.
- Melanoma mortality is higher in Utah than in any other state, shows reporton April 12, 2021 at 8:52 pm
A letter published today [April 8, 2021] by Huntsman Cancer Institute (HCI) at the University of Utah (U of U) in the New England Journal of Medicine reports that melanoma mortality among Utahns ...
- Novel immunotherapy approach may offer therapeutic advantages for melanomaon April 12, 2021 at 1:06 pm
In a new study led by Yale Cancer Center, researchers have advanced a tumor-targeting and cell penetrating antibody that can deliver payloads to stimulate an immune response to help treat melanoma.
- Study shows novel immunotherapy approach to fight melanomaon April 12, 2021 at 9:45 am
In this study, using mice with melanoma tumors, members of the Glazer lab at Yale achieved almost complete tumor suppression upon intravenous injection of antibody/RNA complexes. "These results ...
The Latest Google Headlines on:
Melanoma
The Latest Bing News on:
Photodynamic therapy
- Actinic Keratosis Treatment Market Size Estimated to Reach $7.8 Billion by 2026on April 16, 2021 at 11:59 pm
Rise in the Adoption of Minimally Invasive Treatments Driving the Growth of Actinic Keratosis Treatment Market. Actinic Keratosis Treatment Market size is estimated to reach $7.8 billion by 2026, ...
- Photomedicine Technologies Market Size Forecast to Reach $583.2 Million by 2026on April 14, 2021 at 5:15 pm
Photodynamic Therapy held the largest share in the Photomedicine Technologies Market in 2020 and is estimated to grow at a CAGR 6.7% during the forecast period 2021-2026. The largest share is ...
- Simphotek, Inc Announces NIH Grant for Development of an In Situ System for Treatment of Mesotheliomaon April 13, 2021 at 8:11 pm
NEWARK, NJ, UNITED STATES, April 13, 2021 /EINPresswire.com / -- Simphotek, Inc., an early-stage biotechnology company advancing its computational platform Dosie™ to assist cancer treatment with ...
- Soligenix Announces Presentations at Prominent Scientific Conferenceson April 13, 2021 at 4:10 am
HyBryte™ (SGX301) is a novel, first-in-class, photodynamic therapy utilizing safe, visible light for activation. The active ingredient in HyBryte™ is synthetic hypericin, a potent ...
- Biofrontera reports results for the 2020 financial yearon April 12, 2021 at 12:57 pm
The company’s lead product is the combination of Ameluz, a topical prescription drug, and medical device BF-RhodoLED for the photodynamic therapy of certain superficial skin cancers and their ...
- Biofrontera reports results for the 2020 financial yearon April 12, 2021 at 10:57 am
Operational and clinical developments in 2020 and year-to-date Reorganization of the US business and restructuring of Biofrontera’s global sales organization; Exclusive license and supply agreement ...
- Port wine to treat skin diseaseson April 10, 2021 at 12:03 pm
Researchers from the Faculty of Sciences of the University of Porto (FCUP) have identified molecules, from Port wine, which can be used in the development of drugs for the treatment of skin diseases, ...
- Rocky Hill biotech firm raises $4.3 million, set to begin clinical testingon April 8, 2021 at 5:00 pm
Rocky Hill-based medical technology firm Lumeda, which is developing a lung cancer-killing light therapy system, raised $4.3 million through its Series A funding round and now expects to start human ...
- Tailoring photosensitive ROS for advanced photodynamic therapyon April 8, 2021 at 10:19 am
Photodynamic therapy (PDT) has been considered a noninvasive and cost-effective modality for tumor treatment. However, the complexity of tumor microenvironments poses challenges to the implementation ...
- Soligenix Receives Conditional FDA Acceptance of Proposed Brand Name HyBryte™ for SGX301 in CTCLon April 7, 2021 at 4:12 am
About HyBryte™ HyBryte™ (SGX301) is a novel first-in-class photodynamic therapy utilizing safe visible light for activation. The active ingredient in HyBryte™ is synthetic hypericin ...
